2,6-Dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol → HCID 66716101, Verbindung
Reaktionsgleichung
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12]([CH:14]1[CH2:16][CH2:15]1)=[O:13])=[C:5]2[NH:17][C:18]1[CH:19]=[N:20][N:21]([CH:23]2[CH2:28][CH2:27][CH2:26][N:25]([CH3:29])[CH2:24]2)[CH:22]=1.[Cl:30][C:31]1[CH:36]=[C:35](B2OC(C)(C)C(C)(C)O2)[CH:34]=[C:33]([Cl:46])[C:32]=1[OH:47]>>[CH:14]1([C:12]([C:6]2[CH:7]=[N:8][C:9]3[C:4]([C:5]=2[NH:17][C:18]2[CH:19]=[N:20][N:21]([CH:23]4[CH2:28][CH2:27][CH2:26][N:25]([CH3:29])[CH2:24]4)[CH:22]=2)=[CH:3][C:2]([C:35]2[CH:36]=[C:31]([Cl:30])[C:32]([OH:47])=[C:33]([Cl:46])[CH:34]=2)=[CH:11][CH:10]=3)=[O:13])[CH2:15][CH2:16]1Komponenten
3
Versuchsvorschrift
Following general procedure F, {6-Bromo-4-[1-(1-methylpiperidin-3-yl)-1H-pyrazol-4-ylamino]quinolin-3-yl}(cyclopropyl)methanone (53 mg, 0.110 mmol) was reacted with 2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (47 mg, 0.165 mmol) to afford the desired product (50 mg, 84%) as a green-yellow solid: 1H NMR (500 MHz, DMSO-d6) δ 10.83 (s, 1H), 9.06 (s, 1H), 8.23 (d, J=2.1 Hz, 1H), 8.04 (dd, J=8.7, 2.1 Hz, 1H), 7.93-7.85 (m, 2H), 7.50 (s, 2H), 7.43 (s, 1H), 4.22-4.12 (m, 1H), 2.94 (d, J=11.4 Hz, 2H), 2.88-2.79 (m, 1H), 2.39 (s, 3H), 2.27-2.20 (m, 2H), 2.02-1.89 (m, 4H), 1.02-0.91 (m, 4H); ESI MS m/z 536 [C28H27Cl2N5O2+H]+; HPLC 98.6% (AUC), tR=10.40 min.